Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

John A. Auchampach PhD
Professor
Department of Pharmacology and Toxicology

OFFICE ADDRESS:
Medical Education Building
8701 Watertown Plank Rd
Milwaukee, WI 53226

EDUCATION:
1983 - 1988 BS - Pharmacy, South Dakota State College of Pharmacy, Brookings, SD
1988 - 1992 PhD - Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
1992 - 1993 Postdoctoral Fellow, Molecular Pharmacology, Upjohn Laboratories, Kalamazoo, MI
1993 - 1995 Postdoctoral Fellow, Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA
2015 - 2016 Leadership Training, Lubar School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI

FACULTY APPOINTMENTS:
1995 - 2000 Assistant Professor, Department of Medicine (Cardiology), University of Louisville, Louisville, KY
1998 - 2001 Associate Appointment, Department of Physiology and Biophysics, University of Louisville, Louisville, KY
2000 - 2001 Associate Professor, Department of Medicine (Cardiology), University of Louisville, Louisville, KY
2001 - 2008 Associate Professor, Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI
2008 - Present Professor with tenure, Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS:
2006 - Present Graduate Program Director, Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI
2016 - Present Vice Chairman, Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI
2018 - Present Co-Leader - Cardiac Biology and Heart Failure Affinity Group, Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
2005 - 2009 Course Director (Graduate School) - Advanced Cellular Signal Transduction, Pharmacology & Toxicology, Medical College of Wisconsin, WI
2018 - Present Course Co-Director (Medical School) - Principles of Drug Action, Pharmacology & Toxicology, Medical College of Wisconsin, WI

RESEARCH ADMINISTRATIVE APPOINTMENTS:
2003 Confocal Core Facility Director, Cardiovascular Center, Medical College of Wisconsin, WI
2006 - 2019 Ultrasound Imaging and Rodent Physiology Core Director, Cardiovascular Center, Medical College of Wisconsin, WI
2019 - Present Shared Ultrasound Small Animal Imaging Facility, Pharmacology & Toxicology, Medical College of Wisconsin, WI

AWARDS AND HONORS:
1991 - 1992 Predoctoral Fellowship, American Heart Association - Wisconsin Affiliate
1991 Research Award, International Society for Heart Research
1992 Outstanding Dissertation Award, Friends of MCW, Medical College of Wisconsin
1992 Young Investigator Travel Award, International Society for Heart Research
1993 - 1995 National Research Service Award, National Institutes of Health
1998 - Present Fellow of the American Heart Association (elected)
1999 Extramural Funding Award, Jewish Hospital Research Foundation, Louisville, KY
2006 Outstanding Teacher Award, Graduate Student Association, Medical College of Wisconsin
2009 Outstanding Medical Student Teacher, Medical College of Wisconsin
2010 Outstanding Medical Student Teacher, Medical College of Wisconsin
2011 Outstanding Medical Student Teacher, Medical College of Wisconsin
2011 Top Reviewer, Circulation Research - published by the American Heart Association
2013 Outstanding Medical Student Teacher, Medical College of Wisconsin
2014 Outstanding Medical Student Teacher, Medical College of Wisconsin
2015 Outstanding Medical Student Teacher, Medical College of Wisconsin
2016 Outstanding Graduate School Educator, Medical College of Wisconsin
2017 Outstanding Medical Student Teacher, Medical College of Wisconsin
2018 Outstanding Medical Student Teacher, Medical College of Wisconsin
2019 Outstanding Medical Student Teacher, Medical College of Wisconsin
2020 - 2021 Anytime submission status due to frequent study section service, NIH

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
1990 - 2001 International Society for Heart Research (Member)
1990 - Present American Heart Association (Member)
1996 - Present American Society of Pharmacology and Experimental Therapeutics (Member)
2007 - 2009 Faculty of 1000 Biology (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorial Board
1997 - 2016 American Journal of Physiology
2007 - Present Journal of Pharmacology and Experimental Therapeutics
2007 - Present Inflammation
2011 - 2019 Circulation Research
Journal Review
Microcirculation
Basic Research in Cardiology
FASEB Journal
Inflammation
Journal of Cellular Biochemistry
Molecular Pharmacology
Circulation
American Journal of Physiology
British Journal of Pharmacology
Cardiovascular Research
Hypertension
Journal of Molecular and Cellular Cardiology
Journal of Pharmacology and Experimental Therapeutics
Biochemical Pharmacology
Circulation Research
Proceedings of the National Academy of Sciences US
Journal of Nanobiotechnology
PLoS ONE
Journal of Molecular Medicine
Nature
Purinergic Signalling
Journal of Biological Chemistry
Journal of Clinical Investigation
Diabetes
JCI Insight
Anesthesiology
Journal of Cardiovascular Pharmacology

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2003 - 2005 Member, Board of Directors, American Heart Association Metro Milwaukee

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
1998 - 2000 Member, Great America One Study Section, American Heart Association
1998 Grant Reviewer, NIH Multidisciplinary Sciences Special Emphasis Panel, Surgery, Radiology, and Bioengineering
2000 Grant Reviewer, NIH Multidisciplinary Sciences Special Emphasis Panel, Surgery, Radiology, and Bioengineering
2001 Member, Cardiovascular Physiology and Pharmacology Study Section, American Heart Association
2004 - 2005 Grant Reviewer, External Research Grant Program, Philip Morris
2004 - 2006 Member, Molecular Signaling 2 Study Section, American Heart Association
2005 - Present Ad Hoc Reviewer, Myocardial Ischemia and Metabolism Study Section, NIH (recent participation dates: 2/15/2018, 4/3/2019, 6/20/2019, 2/20/2020, 3/26/2020)
2006 - Present Committee Member, Cardiovacular Pharmacology Division Program Committee, American Society for Pharmacology and Experimental Therapeutics
2007 - 2009 External Advisory Committee Member, Center for Biomedical Research Excellence (COBRE) Program External Review Committee Member, University of Nevada, Reno (Chloride Channel Function and Role in Cardiovascular Disease), NIH
2008 - Present Ad Hoc Reviewer, SBIR/STTR Integrated Review Group, NIH Cardiovascular Sciences (recent participation dates: 11/18/2018, 11/14/2019, 11/11/2020)
2009 Ad Hoc Reviewer, Special Emphasis Panel ZRG1 CVRS-B (58) R and ZRG1 CVRS-B (53), NIH
2013 - 2016 Protocol Review and Monitoring Committee Member, Preclinical Consortium to Facilitate Translation of Cardioprotective Strategies, National Heart Lung and Blood Institute

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Tip60, Ischemic Heart Disease and Regeneration
Source:
NIH (R01)
Role:
Principal Investigator
PI:
Multi-PI (contact) with John Lough
Dates:
12/15/2016 - 11/30/2021
Direct Funds:
$1,308,684
 
Title:
Adenosine Signaling During Post-Infarction Remodeling and Heart Failure
Source:
NIH (R01)
Role:
Principal Investigator
Dates:
02/15/2017 - 01/31/2022
Direct Funds:
$1,135,649
 
Title:
Cannabinoid-Mediated Mitigation of Graft Versus Host Disease: Roles of CB2 Receptors and Adenosine Signaling
Source:
NIH (R01)
Role:
Co-Investigator
PI:
William Drobyski
Dates:
08/01/2017 - 06/30/2021
Direct Funds:
$1,407,120
 
Pending
Peer Review
Title:
Targeting Tip60 for Heart Repair
Source:
NIH (R01)
Role:
Principal Investigator
PI:
Multi-PI (contact) with John Lough
Dates:
12/01/2020 - 11/30/2025
Direct Funds:
$1,979,567
 
Title:
Targeting the Purinergic Pathway by Roseoloviruses
Source:
NIH (R01)
Role:
Co-Investigator
PI:
Amy Hudson
Dates:
07/01/2021 - 06/30/2026
Direct Funds:
$1,980,034
 
Title:
Discovery of Adenosine Receptor Allosteric Modulators for Cardiovascular Disease and Inflammation
Source:
NIH (R01)
Role:
Principal Investigator
Dates:
12/01/2021 - 11/30/2026
Direct Funds:
$1,125,000
 
Title:
Tip60beta, a Putative Inducer of Proliferative Senescence in Neonatal Cardiomyocytes
Source:
NIH (R01)
Role:
Principal Investigator
PI:
Multi-PI (contact) with John Lough
Dates:
12/01/2021 - 11/30/2026
Direct Funds:
$1,470,010
 
Prior
Peer Review
Title:
Role of ATP-Dependent Potassium Channels in Myocardial Ischemia/Reperfusion Injury
Source:
American Heart Association (Predoctoral Fellowship)
Role:
Principal Investigator
Dates:
07/01/1990 - 06/30/1992
Direct Funds:
$17,800
 
Title:
Molecular Cloning and Pharmacological Characterization of Adenosine Receptors
Source:
NIH (NRSA Postdoctoral Fellowship)
Role:
Principal Investigator
Dates:
09/01/1994 - 08/30/1995
Direct Funds:
$46,100
 
Title:
Molecular Pharmacology of Adenosine Receptors
Source:
University of Louisville School of Medicine
Role:
Principal Investigator
Dates:
05/01/1996 - 04/30/1997
Direct Funds:
$10,000
 
Title:
Role of A3 Adenosine Receptors in the Ischemic Myocardium
Source:
American Heart Association (Scientist Development Grant)
Role:
Principal Investigator
Dates:
01/01/1997 - 12/31/2000
Direct Funds:
$260,000
 
Title:
Pathobiology of Ischemic Heart Disease: Role of KATP Channels
Source:
Jewish Hospital Research Foundation (Louisville, Kentucky)
Role:
Principal Investigator
Dates:
01/01/1997 - 12/30/1998
Direct Funds:
$100,000
 
Title:
Development of Mice with Cardiac-Specific Overexpression of the A3 Adenosine Receptor
Source:
NIH (supplement)
Role:
Principal Investigator
Dates:
01/01/1998 - 12/31/1998
Direct Funds:
$20,000
 
Title:
A3 Adenosine Receptors: Molecular Pharmacology and Function in the Ischemic Myocardium
Source:
NIH (FIRST Award)
Role:
Principal Investigator
Dates:
03/01/1998 - 02/28/2009
Direct Funds:
$1,850,000
 
Title:
Effect of Cardiac-Specific Overexpression of the A3 Adenosine Receptor on Tolerance to Ischemic Injury
Source:
American Heart Association (Postdoctoral Fellowship)
Role:
Sponsor
PI:
Ken Shinmura
Dates:
07/01/1999 - 06/30/2001
Direct Funds:
$59,000
 
Title:
Role of the A3 Adenosine Receptor and Mast Cells in Myocardial Ischemia/Reperfusion Injury
Source:
American Heart Association (Postdoctoral Fellowship)
Role:
Sponsor
PI:
Zhi-Dong Ge
Dates:
07/01/2002 - 06/30/2004
Direct Funds:
$75,000
 
Title:
Cytochrome P-450 Eicosanoids and Myocardial Injury
Source:
NIH (R01)
Role:
Co-Investigator
PI:
Garrett J. Gross
Dates:
07/01/2003 - 06/30/2013
Direct Funds:
$1,400,000
 
Title:
Molecular Characterization of Splice Variants of the A2B Adenosine Receptor
Source:
American Heart Association (Predoctoral Fellowship)
Role:
Sponsor
PI:
Laura Kreckler
Dates:
07/01/2003 - 06/30/2005
Direct Funds:
$52,000
 
Title:
Effect of Drugs on Myocardial Hypoxia
Source:
NIH (R01)
Role:
Co-Investigator
PI:
Garrett J. Gross
Dates:
12/01/2004 - 11/30/2009
Direct Funds:
$1,125,000
 
Title:
Endoderm Induction of Cardiac Myocytes from ES Cells
Source:
NIH (R01)
Role:
Co-Investigator
PI:
John Lough
Dates:
07/01/2005 - 05/31/2009
Direct Funds:
$900,000
 
Title:
Inducible Tissue-Specific Deletion of the A3 Adenosine Receptor
Source:
NIH (NRSA Postdoctoral Fellowship)
Role:
Sponsor
PI:
Tina C. Wan
Dates:
07/01/2006 - 06/30/2008
Direct Funds:
$80,000
 
Title:
Characterization of Regulatory Roles of A2A and A3 Adenosine Receptors in Neutrophils
Source:
American Heart Association (Predoctorl Fellowship)
Role:
Sponsor
PI:
Dharini van der Hoeven
Dates:
07/01/2006 - 06/30/2008
Direct Funds:
$52,000
 
Title:
The Role of the A2B Adenosine Receptor in Heart Failure
Source:
American Heart Association (Predoctoral Fellowship)
Role:
Sponsor
PI:
Jason E. Maas
Dates:
01/01/2008 - 12/30/2009
Direct Funds:
$52,000
 
Title:
Regeneration of Infarcted Myocardium with Isl1+ Cells
Source:
Advancing a Healthier Wisconsin
Role:
Co-Investigator
PI:
John Lough
Dates:
04/01/2008 - 07/31/2009
Direct Funds:
$50,000
 
Title:
Anesthetic-Induced Cardiac Preconditioning
Source:
NIH (P01)
Role:
Co-Investigator
PI:
Zeljko Bosnjak
Dates:
08/01/2008 - 07/31/2013
Direct Funds:
$1,400,000
 
Title:
Induction of Cardiovascular Cells from hESCs by Embryonic Cues
Source:
NIH (P01)
Role:
Core Director
PI:
John Lough
Dates:
08/01/2009 - 11/01/2014
Direct Funds:
$1,600,000
 
Title:
Role of Adenosine Receptors in Tissue Protection
Source:
NIH (R01)
Role:
Principal Investigator
Dates:
01/01/2011 - 05/31/2015
Direct Funds:
$1,120,000
 
Title:
EET-Induced Cardioprotection: Role of Opioids and Nitric Oxide
Source:
NIH (R01)
Role:
Principal Investigator
Dates:
09/01/2011 - 12/31/2018
Direct Funds:
$1,610,120
 
Title:
Summer Undergraduate Summer Fellowship Program
Source:
American Society for Pharmacology and Experimental Therapeutics
Role:
Program Director
Dates:
05/01/2013 - 10/01/2015
Direct Funds:
$37,500
 
Title:
Signaling Mechanisms During Cardiac Regeneration
Source:
Medical College of Wisconsin Cardiovascular Center
Role:
Principal Investigator (Contact PI) - Multi-PI with Brian Link, John Lough, & Caitlin O'Meara
Dates:
07/01/2017 - 06/30/2020
Direct Funds:
$200,000
 
Title:
A3 Adenosine Receptor Allosteric Modulators for Chronic Neuropathic Pain
Source:
Therapeutic Accelerator Program
Role:
Principal Investigator
Dates:
2017 - 2018
Direct Funds:
$5,000
 
Title:
VisualSonics Vevo 3100 High-Frequency Ultrasound Imaging System
Source:
NIH (S10)
Role:
Principal Investigator
Dates:
08/01/2019 - 07/31/2020
Direct Funds:
$301,950
 
Non-Peer Review
Title:
Characterizing the Binding Affinity of Gilead A2B Receptor Antagonists
Source:
Gilead Sciences
Role:
Principal Investigator
Dates:
01/27/2011 - 10/30/2011
Direct Funds:
$6,597
 

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Seminar, Department of Pharmacology, Medical College of Wisconsin, Milwaukee, WI, 1997
Seminar, Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, 2002
Seminar, Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 2003
Cardiology Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 2008
Meeting of the Cardiovascular Center Board of Directors, Medical College of Wisconsin, Milwaukee, WI, 2009
Research Presentation, First Annual Translational Symposium in Cardiovascular Sciences, Milwaukee, WI, 2009
"Work in Progress" seminar, Medical College of Wisconsin Cardiovascular Center, Milwaukee, WI, 2010
Cardiology Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 2011
"Work-in-Progress" seminar, Medical College of Wisconsin Cardiovascular Center, Milwaukee, WI, 2012
"Research-in-Progress" presentation, Department of Pharmacology, Medical College of Wisconsin, Milwaukee, WI, 2013
Drug Repurposing Interest Group, Medical College of Wisconsin, Milwaukee, WI, 2016
Hippo Signaling in Neuro and Muscular Biology, Milwaukee, WI, 2017
Cardiovascular Center Team Science Research Symposium, Medical College of Wisconsin, Milwaukee, WI, 2017
Seminar, Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 2018
Cardiovascular Center Team Science Research Symposium, Medical College of Wisconsin, Milwaukee, WI, 2018
Seminar, Department of Pharmacology, Medical College of Wisconsin, Milwaukee, WI, 2019
 
National
International Society for Heart Research, American Section, Burlington, VT, 1992
5th World Congress of the International Society for Adaptive Medicine, Framingham, MA, 1997
Cardiology Grand Rounds, University of Louisville, Louisville, KY, 1998
Seminar, Department of Pharmacology, University of Virginia, Charlottesville, VA, 2000
Seminar, Department of Pharmacology, Biogen, Inc., Boston, MA, 2000
International Society for Heart Research, Louisville, KY, 2000
Seminar, Department of Anesthesiology, University of Louisville, Louisville, KY, 2000
12th International Symposium on Adenosine, Chicago, IL, 2002
International Society for Heart Research, Mystic, CT, 2003
Experimental Biology, San Francisco, CA, 2006
Seminar, Department of Medicine, New York University, New York, NY, 2006
Seminar, Department of Pharmacology, University of Pittsburgh, Pittsburgh, PA, 2007
Seminar, Cardiovascular Institute, Loyolla University, Chicago, IL, 2008
Research Presentation, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 2012
Research Presentation, American Heart Association Scientific Sessions, Dallas, TX, 2013
Research Presentation, Cardiovascular Center, Ohio State University, Columbus, OH, 2016
 
International
XIVth Congress of the European Society of Cardiology, Barcelona, Spain, 1992
2nd Winterpanel in Cardiology, Zermatt, Switzerland, 1993
6th International Symposium on Adenosine and Adenine Nucleotides, Milan, Italy, 1998
Purines 2000, Madrid, Spain, 2000
7th International Symposium on Adenosine and Adenine Nucleotides, Gold Coast, Australia, 2002
34th International Narcotics Research Conference, Perpignan, France, 2003
8th International Symposium on Adenosine and Adenine Nucleotides, Ferrara, Italy, 2006
Purines 2008, Copenhagen, Denmark, 2008
Purines 2014, Bonn, Germany, 2014
Keystone Symposia - Purinergic Signaling, Vancouver, Can, 2016
Purines 2018, Milan, Italy, 2018
 

COMMITTEE SERVICE:
Medical College of Wisconsin
2000 - 2001 Member, Animal Care and Use Committee, University of Louisville
2000 - 2001 Member, Use of Genetic Materials Advisory Committee, University of Louisville
2003 - 2006 Member, Graduate Student Recruitment Committee - Interdisciplinary Program of Biomedical Sciences, Medical College of Wisconsin
2003 - 2008 Member, Graduate Student Mentoring Committee - Interdisciplinary Program in Biomedical Sciences, Medical College of Wisconsin
2004 - 2008 Member, Faculty Search Committee, Department of Pharmacology, Medical College of Wisconsin
2004 - 2006 Member, Library Committee, Medical College of Wisconsin
2006 - 2007 Member, Biomedical Resource Center Director Search Committee, Medical College of Wisconsin
2006 - Present Member, Graduate Studies Council, Medical College of Wisconsin
2007 - 2010 Member, Graduate Studies Council Program Evaluation Committee, Medical College of Wisconsin
2008 - 2010 Chairman, Graduate Studies Council Program Evaluation Committee, Medical College of Wisconsin
2009 - 2010 Member, Medical Education Integration Council, Medical College of Wisconsin
2009 - 2010 Member, Medical School Curriculum Committee - Cardiovascular/Renal/Respiratory module, Medical College of Wisconsin
2012 - 2014 Member, Discovery Curriculum Expert Panel (Cardiovascular Unit), Medical College of Wisconsin
2013 - 2014 Member, Inflammation and Immunology Work Group, Medical College of Wisconsin
2014 - Present Member, Faculty Mentoring Committee, Medical College of Wisconsin
2014 - 2015 Member, Pharmacy School Internal Advisory Committee, Medical College of Wisconsin
2015 - Present Member, Program Directors Committee - Interdisciplinary Program in Biomedical Sciences, Medical College of Wisconsin
2016 - Present Member, Cardiovascular Center Equipment Committee, Medical College of Wisconsin
2016 - 2017 Member, Pharmacy School Faculty Search Committee, Medical College of Wisconsin
2017 - 2018 Physiology Department Chair Search Committee, Medical College of Wisconsin
2017 - 2018 Chairman, Cardiovascular Center Postdoctoral Recruitment Committee, Medical College of Wisconsin
 

MEDICAL COLLEGE TEACHING ACTIVITIES:
Medical Student Education
2001 - Present Principles of Drug Action (M1 Course): Autonomic nervous system pharmacology, neuromuscular junction blocking agents, local anesthetics, pharmacokinetics & pharmacodynamics
2010 - Present Cardiovascular Unit (M2 Course): Review of Cardiac Function and Myocardial Oxygen Supply/Demand Balance; Heart Failure (Topic Leader); Ischemic Heart Disease/Acute Coronary Syndromes (Topic Leader); Cardiovascular Pharmacology Review
2011 - Present Symptoms-Based Module (M2 Course): Syncope
 
Graduate Student Education
2003 - 2009 Advanced Cellular Signal Transduction Course (Pharmacology Graduate Program) - G protein-coupled receptors and G protein regulation of ion channels
2003 - 2005 Biochemistry Course (Interdisciplinary Progam in Biomedical Sciences) - Signal transduction by cytokine receptors, enzyme-linked receptors, and integrins
2005 - 2019 Cellular Signal Transduction Course (Interdisciplinary Program in Biomedical Sciences) - G protein-coupled receptors, heterotrimeric G proteins, signaling by cAMP
2009 - 2019 Advanced Cellular Signal Transduction Course (Pharmacology Graduate Program) - beta adrenergic receptor blockers
2017 - Present Fundamentals of Neuroscience (Neuroscience Graduate Program) - Autonomic Nervous System
2019 - Present Understanding Cell Signaling Through Study of Therapeutic Drugs (Interdisciplinary Program in Biomedical Sciences) - Adrenergic Receptors
2019 - Present Foundations in Biomedical Sciences III (Interdisciplinary Program in Biomedical Sciences) - Introduction to cellular signaling, G protein-coupled receptors, heterotrimeric G proteins
 

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Graduate Students
PhD Committees
Yunfei Cai, Medical College of Wisconsin, 1997 - 2002 Pharmacology & Toxicology
Ryan M. Fryer, Medical College of Wisconsin, 1997 - 2001 Pharmacology & Toxicology
Tamara Maier, Medical College of Wisconsin, 1998 - 2003 Pharmacology & Toxicology
Hemal Patel, Medical College of Wisconsin, 1998 - 2002 Pharmacology & Toxicology
Linda Ludwig, Medical College of Wisconsin, 1999 - 2004 Pharmacology & Toxicology
Wenqi Yang, Medical College of Wisconsin, 1999 - 2004 Pharmacology & Toxicology
Xinrong Lu, Medical College of Wisconsin, 1999 - 2004 Pharmacology & Toxicology
Erica J. Carrier, Medical College of Wisconsin, 2000 - 2005 Pharmacology & Toxicology
Rebecca Moyer, Medical College of Wisconsin, 2003 - 2008 Microbiology and Molecular Genetics
Leyu Shi, Medical College of Wisconsin, 2004 - 2009 Pharmacology & Toxicology
James Schuman, Medical College of Wisconsin, 2005 - 2010 Microbiology and Molecular Genetics
Jimmy Crockett, Medical College of Wisconsin, 2005 - 2010 Pharmacology & Toxicology
Eryn Hassemer, Medical College of Wisconsin, 2005 - 2010 Cell Biology, Neurobiology, and Anatomy
Jamie Privratsky, Medical College of Wisconsin, 2006 - 2010 Medical-Scientist Training Program, Pharmacology
Elizabeth Ntante, Medical College of Wisconsin, 2007 - 2012 Pharmacology & Toxicology
Christopher Roberts, Medical College of Wisconsin, 2008 - 2011 Medical-Scientist Training Program, Pharmacology
Adam Gastonguay, Medical College of Wisconsin, 2008 - 2012 Pharmacology & Toxicology
Jackie Porath, Medical College of Wisconsin, 2008 - 2013 Pharmacology & Toxicology
Lawan Siangjong, Medical College of Wisconsin, 2009 - 2013 Pharmacology & Toxicology
Nathan Schuld, Medical College of Wisconsin, 2009 - 2014 Pharmacology & Toxicology
Jessica Wilson, Medical College of Wisconsin, 2012 - 2015 Medical-Scientist Training Program, Pharmacology
Mike Tanner, Medical College of Wisconsin, 09/01/2013 - 2016 Pharmacology & Toxicology
Andrew Kleist, Medical College of Wisconsin, 2015 - 2019 Medical-Scientist Training Program, Biochemistry
Rachel Schlaak, Medical College of Wisconsin, 2015 - Present Pharmacology & Toxicology
Michelle Storage, Medical College of Wisconsin, 2016 - Present Cell Biology, Neurobiology & Anatomy
Valery Lozada-Fernandez, Medical College of Wisconsin, 2017 - Present Microbiology and Immunology
Ayana Jamal, Medical College of Wisconsin, 2018 - Present Medical-Scientist Training Program, Cell Biology, Neurobiology & Anatomy
Olivia Koehn, Medical College of Wisconsin, 2019 - Present Pharmacology & Toxicology
Valeria Robleto, Medical College of Wisconsin, 2020 - Present Biochemistry
PhD Students Advised
Laura M. Kreckler Ph.D., Medical College of Wisconsin, 2002 - 2006 Modulation of Macrophage Cytokine Production by Adenosine
Dharini van der Hoeven, Ph.D., Medical College of Wisconsin, 2005 - 2008 A3 Adenosine Receptor-Medicated Suppression of the Pro-Inflammatory Functions of Mouse Bone Marrow Neutrophils through Inhibition of Rac
Jordan Van Orman, M.D., Ph.D., Medical College of Wisconsin, 2005 - 2009 Role of the Micro-Environment on Embryonic Stem Cell Cardiogenesis
Jason Maas, M.D., Ph.D., Medical College of Wisconsin, 2006 - 2010 Role of the A2B Adenosine Receptor in Cardiovascular Disease
Lili Du, Ph.D., Medical College of Wisconsin, 2008 - 2012 Allosteric Modulation of the A3 Adenosine Receptor
Shraddha Nayak, Medical College of Wisconsin, 2011 - 2015 Development of a novel Adora2b transgenic rat and role of A2B adenosine receptors in hypertension
Courtney Fisher, Medical College of Wisconsin, 2019 - Present Pharmacology & Toxicology
 
Postdoctoral Students
Zhi-Dong (Wilson) Ge, M.D., Ph.D., Medical College of Wisconsin, 2001 - 2005
Tina C. Wan, Ph.D., Medical College of Wisconsin, 2002 - 2006
Xinrui (Sarea) Wang, Ph.D., Medical College of Wisconsin, 2018 - Present
 

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
Postdoctoral Students
Hitoshi Takano, M.D., University of Louisville, 1998 - 1999
Eitaro Kodani, M.D., University of Louisville, 1999 - 2000
Ken Shinmura, M.D., Ph.D., University of Louisville, 1999 - 2001
 

PATENTS:
2004 - Present Methods of Treating Ischemia Reperfusion Injury Using Adenosine Receptor Antagonists (#20050203065)
2019 - Present Tip60 Inhibitors and Methods for Use for Cardiovascular Disease (provisional)


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Auchampach JA, Maruyama M, Cavero I, Gross GJ (1991). The new K+ channel opener RP 52891 (Aprikalim) reduces experimental infarct size in the absence of hemodynamic changes. Journal of Pharmacology and Experimental Therapeutics 269:961-967.
2. Gross GJ, Auchampach JA (1992). Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circulation Research 70:223-233.
3. Auchampach JA, Maruyama M, Cavero I, Gross GJ (1992). Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation 86:311-319.
4. Auchampach JA, Grover GJ, Gross GJ (1992). Blockade of ischemic preconditioning in dogs by the novel ATP-dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovascular Research 26:1054-1062.
5. Auchampach JA, Cavero I, Gross GJ (1992): Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. Journal of Cardiovascular Pharmacology 20:765-771.
6. Auchampach JA, Gross GJ (1993): Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. American Journal of Physiology 33:H1327-H1336.
7. Yao Z, Auchampach JA, Pieper GM, Gross GJ. (1993). Monophospholipid A increases catalase activity and reduces myocardial infarct size in dogs. Cardiovascular Research 27:832-838.
8. Auchampach JA, Gross GJ (1993): Reduction in myocardial infarct size by the new potassium channel opener bimakalim. Journal of Cardiovascular Pharmacology 23:554-561.
9. Warltier DC, Auchampach JA, Gross GJ (1993). Relationship of severity of myocardial stunning to ATP-dependent potassium channel modulation. Journal of Cardiovascular Surgery 8:279-283.
10. Hillard CJ, Auchampach JA (1994). In vitro activation of brain protein kinase C by the cannabinoids. Biochimica et Biophysica Acta 1220:163-170.
11. Auchampach JA, Oliver MJ, Anderson DC, Manning AM (1994). Cloning, sequence comparison, and in vivo expression of the gene encoding rat P-selectin. Gene 145:251-255.
12. Manning AM, Auchampach JA, Drong RF, Slightom JL (1995). Cloning of the cDNA homologous to the human transforming growth factor-beta1-encoding gene. Gene 155:307-308.
13. Griffin RL, Krzesicki RF, Fidler SF, Rosenbloom CL, Auchampach JA, Manning AM, Haas JV, Cammarata SK, Chin J, Richards IM (1995). Attenuation of oxidant-induced lung injury by 21-aminosteroids (Lazaroids): Correlation with the mRNA expression for E-selectin, P-selectin, ICAM-1, and VCAM-1. Environmental Health Perspectives 102(Suppl 10):193-200.
14. Mizimura T, Auchampach JA, Linden J, Bruns RF, Gross GJ (1996). PD 81,723, an allosteric enhancer of the adenosine A1 receptor, lowers the threshold for ischemic preconditioning in dogs. Circulation Research 79:415-423.
15. Auchampach JA, Rizvi A, Qiu Y, Tang X-L, Maldonado C, Teschner S, Bolli R (1997). Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circulation Research 80:800-806.
16. Maldonado C, Qiu Y, Tang X-L, Cohen MV, Auchampach J, Bolli R (1997). Role of adenosine A1 receptors in late preconditioning against myocardial stunning in conscious rabbits. American Journal of Physiology 273:H1324-H1332.
17. Auchampach JA, Jin X, Wan TC, Caughey G, Linden J (1997). Canine mast cell adenosine receptors: Cloning and expression of the A3 adenosine receptor and evidence that degranulation is mediated by the A2B receptor. Molecular Pharmacology 52:846-860.
18. Auchampach JA, Maruyama M, Cavero I, Gross GJ (1998). Effect of the platelet-activating factor antagonist RP 59227 on myocardial ischemia/reperfusion injury and neutrophil activation. Basic Research in Cardiology 93:361-371.
19. Ping P, Zhang J, Cao X. , Li RCX, Kong D, Tang X-L, Qiu Y, Manchikalapudi S, Auchampach JA, Black RG, Bolli R (1999). PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits. American Journal of Physiology 276:H1468-H1481.
20. Jordan JE, Thourani VH, Auchampach JA, Vinten-Johansen J (1999). A3 adenosine receptors: Their role in modulating neutrophil superoxide production, degranulation, adherence to coronary endothelium, and reperfusion injury. American Journal of Physiology 277:H1895-H1905.
21. Gumina RJ, Auchampach JA, Daemmgen J, Gross GJ (2000). Na+/H+ exchange inhibition-induced cardioprotection: Role of neutrophils vs. cardiomyocytes. American Journal of Physiology 279:H1563-H1570.
22. Takano T, Bolli R, Black RG, Jr, Kodani E, Tang XL, Yang Z, Battacharya S, Auchampach JA (2001). Activation of A1 or A3 adenosine receptors induces late preconditioning against infarction in conscious rabbits by different mechanisms. Circulation Research 88:520-528.
23. Guo Y, Bolli R, Bao W, Wu WJ, Black RG, Murphree SS, Salvatore CA, Jacobson MA, Auchampach JA (2001). Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. Journal of Molecular and Cellular Cardiology 33:825-830.
24. Kodani E, Bolli R, Tang XL, Auchampach JA (2001). Protection of IB-MECA against myocardial stunning in conscious rabbits is not mediated by the A1 adenosine receptor. Basic Research in Cardiology 96:487-496.
25. Kodani E, Tang XL, Shinmura K, Auchampach JA, Bolli R (2001). Cyclooxygenase-2 does not mediate late preconditioning against infarction induced by adenosine A1 or A3 receptors. American Journal of Physiology 281:H959-H968.
26. Black RG, Guo Y, Ge ZD, Murphree SS, Prabhu SD, Jones WK, Bolli R, Auchampach JA (2002). Gene dosage dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circulation Research 91:165-172.
27. Cross H, Murphy E, Black RG, Auchampach JA, Steenbergen C (2002). Overexpression of A3 adenosine receptors decreases heart rate, preserves energetics, and protects the ischemic heart. American Journal of Physiology 283:H1562-H1568.
28. Ge ZD, Auchampach JA, Pieper GM, Gross GJ (2003) Evidence that thromboxane does not modulate infarct size using two different thromboxane receptor antagonists. Journal of Cardiovascular Pharmacology. 41: 481-488.
29. Auchampach JA, Ge ZD, Wan TC, Moore J, Gross GJ (2003) The A3 adenosine receptor agonist IB-MECA reduces ischemia-reperfusion injury in dogs. American Journal of Physiology 285:H607-H613.
30. Ticho B, Whalley E, Gill A, Lutterodt F, Jin X, Auchampach JA, Smits G (2003). Renal effects of BG 9928, an A1 adenosine receptor antagonist, in rats and nonhuman primates. Drug Development Research 58:486-492.
31. Fabritz L, Kirchhof P, Fortmüller L, Auchampach JA, Baba HA, Breithardt G, Neumann J, Boknik P, Schmitz W. (2004) Gene dose-dependent atrial arrhythmias, heart block and brady-cardiomyopathy in mice overexpressing A3 adenosine receptors. Cardiovascular Research 62:500-508.
32. Auchampach JA, Jin X, Moore J, Wan TC, Kreckler LM, Ge ZD, Narayanan J, Whalley E, Kiesman W, Ticho B, Smitts G, Gross GJ. (2004) Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. Journal of Pharmacology and Experimental Therapeutics 308:846-856.
33. Gross ER, Peart JN, Hsu AK, Auchampach JA, Gross GJ (2005). Extending the cardioprotective window by a novel  opioid agonist fentanyl isothiocyanate via the phosphoinositol-3 kinase pathway. American Journal of Physiology 288:H2744-H2749.
34. Kreckler LM, Wan TC, Ge ZD, Auchampach JA (2006). Adenosine inhibits TNF-alpha release from mouse peritoneal macrophages via A2A and A2B, but not A3 adenosine receptors. Journal of Pharmacology and Experimental Therapeutics 317:172-180.
35. Carrier E, Auchampach JA, Hillard CJ (2006). Inhibition of the equilibrative nucleoside transporter by cannabidiol: A novel mechanism of cannabionoid immunosuppression. Proceedings of the National Academy of Sciences USA 103:7895-7900.
36. Nelson TJ, Ge ZD, Van Orman J, Barron M, Rudy-Reil D, Hacker TM, Misra R, Duncan SA, Auchampach JA, Lough J. (2006). Improved cardiac function in infarcted mice after treatment with pluripotent embryonic stem cells. Anatomical Record 288A:1216-1224.
37. Ge ZD, Peart JN, Kreckler LM, Wan TC, van der Hoeven D, Gross GJ, Jacobson MA, Auchampach JA (2006). Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methycarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor. Journal of Pharmacology and Experimental Therapeutics 319:1200-1210.
38. Wan TC, Ge ZD, Bienengraeber MW, Tampo A, Kwok WM, Tracey WR, Gross GJ, Auchampach JA (2008). The A3 adenosine receptor agonist CP-532,903 protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP sensitive potassium channel. Journal of Pharmacology and Experimental Therapeutics 324:234-243.
39. Melman A, Gao ZG, Kumar D, Wan TC, Gizewski E, Auchampach JA, Jacobson KA. (2008) Design of (N)-Methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorganic Medicinal Chemistry Letters 18:2813-2819.
40. van der Hoeven D, Wan TC, and Auchampach JA (2008). Activation of A3 adenosine receptors in mouse bone marrow neutrophils inhibits superoxide production and chemotaxis. Molecular Pharmacology 74:685-696.
41. Liu GI, Auchampach JA, Hillard CJ, Zhu G, Yousufzai B, Mian S, Khan S, Khalifa Y (2008). Mediation of cannabidiol anti-inflammation in the retina by the equilibrative nucleoside transporter and the A2A adenosine receptor. Investigative Journal of Ophthalmology and Vision Science 49:5526-5531.
42. Auchampach JA, Kreckler LM, Wan TC, Maas JE, van der Hoeven D, Gizewski E, Narayanan J, Maas GE. (2009). Pharmacological characterization of A2B adenosine receptors from mouse, rabbit, and dog. Journal of Pharmacology and Experimental Therapeutics 329:2-13.
43. Kreckler LM, Wan TC, Gizewski E, Auchampach JA (2009). Adenosine suppresses LPS-induced TNF-alpha production from murine macrophages by inhibiting gene transcription through a PKA- and EPAC-independent signaling pathway. Journal of Pharmacology and Experimental Therapeutics 331:1051-1061.
44. Ge Z-D, Pravdic D, Kwok C, Bienengraeber MW, Pratt PF, Auchampach JA, Gross GJ, Bosnjak ZJ, Kersten JR, Warltier DC (2010). The cardioprotective effect of isofluorane postconditioning is mediated by eNOS through inhibiting mitochondrial permeability transition in mice. Anesthesiology 112:73-85.
45. Auchampach JA, Gizewski ET, Wan TC, de Castro S, Brown GG, Jacobson KA (2010). Synthesis and pharmacological characterization of [125I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor. Biochemical Pharmacology 79:967-973.
46. van der Hoeven D, Gizewski ET, Auchampach JA (2010). Activation of the A3 adenosine receptor inhibits fMLP-induced Rac activation in mouse bone marrow neutrophils. Biochemical Pharmacology 79:1667-1673.
47. Ge ZD, van der Hoeven D, Maas JE, Wan TC, Auchampach JA (2010). A3 adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells. Journal of Molecular and Cellular Cardiology 49:280-286.
48. Maas JE, Wan TC, Figler RA, Gross GJ, Auchampach JA (2010). Evidence that the acute phase of ischemic preconditioning does not require signaling by the A2B adenosine receptor. Journal of Molecular and Cellular Cardiology 49:886-893.
49. Xiang, S, Ge ZD, Wan TC, Auchampach JA, Gross GJ, Duan D. (2011). Characterization of a critical role of CFTR chloride channels in cardioprotection against ischemia/reperfusion injury. Act Pharmacologica Sinica 32:824-833.
50. van der Hoeven D, Gizewski E, Wan TC, Auchampach JA (2011). A role for the low-affinity A2B adenosine receptor in suppressing superoxide production by neutrophils. Journal of Pharmacology and Experimental Therapeutics 338:1004-1012.
51. Fisher JB, Kim MS, Blinka S, Ge ZD, Wan TC, Duris C, Christian D, Twaroski K, North P, Auchampach JA, Lough J (2012) Stress-induced cell-cycle activation in Tip60 haploinsufficient adult cadiomyocytes. PLos One 72:e31569
52. Du L, Gao ZG, Nithipatikom K, Ijzerman AP, Veldhoven JP, Jacobson KA, Gross GJ, Auchampach JA. Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor. J Pharmacol Exp Ther. 2012 Jan;340(1):210-7. PMCID: PMC3251031
53. Wan TC, Tosh DK, Du L, Gizewski ET, Jacobson KA, Auchampach JA. Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts. BMC Pharmacol. 2011 Oct 31;11:11. PMCID: PMC3247180
54. Tosh DK, Deflorian F, Phan K, Gao ZG, Wan TC, Gizewski E, Auchampach JA, Jacobson KA. Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem. 2012 May 24;55(10):4847-60. PMCID: PMC3371665
55. Chandrasekera PC, Wan TC, Gizewski ET, Auchampach JA, Lasley RD. Adenosine A1 receptors heterodimerize with β1- and β2-adrenergic receptors creating novel receptor complexes with altered G protein coupling and signaling. Cell Signal. 2013 Apr;25(4):736-42. PMCID: PMC3896953
56. Kozma E, Gizewski ET, Tosh DK, Squarcialupi L, Auchampach JA, Jacobson KA (2013). Characterization by flow cytometry of fluorescent, selective agonist probes of the A3 adenosine receptor. Biochemical Pharmacology 85:1171-1181.
57. Ntantie E, Gonyo P, Lorimer EL, Hauser AD, Schuld N, McAllister D, Kalyanaraman B, Dwinell MB, Auchampach JA, Williams CL. An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering. Sci Signal. 2013 May 28;6(277):ra39. PMCID: PMC4278376
58. Paoletta S, Tosh DK, Finley A, Gizewski ET, Moss SM, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA. Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. J Med Chem. 2013 Jul 25;56(14):5949-63. PMCID: PMC3858399
59. Kriska T, Cepura C, Siangjong L, Wan TC, Auchampach JA, Shaish A, Haratz D, Kumar G, Falck JR, Gauthier KM, Campbell WB. Effect of human 15-lipoxygenase-1 metabolites on vascular function in mouse mesenteric arteries and hearts. Prostaglandins Other Lipid Mediat. 2013 Oct;106:8-15. PMCID: PMC3844054
60. Lakshmikanthan S, Zieba BJ, Ge ZD, Momotani K, Zheng X, Lund H, Artamonov MV, Maas JE, Szabo A, Zhang DX, Auchampach JA, Mattson DL, Somlyo AV, Chrzanowska-Wodnicka M. Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure. Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1486-94. PMCID: PMC4224284
61. Tosh DK, Finley A, Paoletta S, Moss SM, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA. In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. J Med Chem. 2014 Dec 11;57(23):9901-14. PMCID: PMC4266358
62. Tosh DK, Crane S, Chen Z, Paoletta S, Gao ZG, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA. Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy. ACS Med Chem Lett. 2015 Jul 09;6(7):804-8. PMCID: PMC4499829
63. Tosh DK, Paoletta S, Chen Z, Crane S, Lloyd J, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA. Structure-Based Design, Synthesis by Click Chemistry and <i>in Vivo</i> Activity of Highly Selective A<sub>3</sub> Adenosine Receptor Agonists. Medchemcomm. 2015;6:555-563. PMCID: PMC4517612
64. Nayak S, Khan MA, Wan TC, Pei H, Linden J, Dwinell MR, Geurts AM, Imig JD, Auchampach JA. Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension. Purinergic Signal. 2015 Dec;11(4):519-31. PMCID: PMC4648794
65. Tosh DK, Ciancetta A, Warnick E, O'Connor R, Chen Z, Gizewski E, Crane S, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA. Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists. J Med Chem. 2016 Apr 14;59(7):3249-63. PMCID: PMC4970510
66. Carlin JL, Jain S, Gizewski E, Wan TC, Tosh DK, Xiao C, Auchampach JA, Jacobson KA, Gavrilova O, Reitman ML. Hypothermia in mouse is caused by adenosine A<sub>1</sub> and A<sub>3</sub> receptor agonists and AMP via three distinct mechanisms. Neuropharmacology. 2017 03 01;114:101-113. PMCID: PMC5183552
67. Tosh DK, Janowsky A, Eshleman AJ, Warnick E, Gao ZG, Chen Z, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA. Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. J Med Chem. 2017 04 13;60(7):3109-3123. PMCID: PMC5501184
68. Densmore JC, Schaid TR, Jeziorczak PM, Medhora M, Audi S, Nayak S, Auchampach J, Dwinell MR, Geurts AM, Jacobs ER. Lung injury pathways: Adenosine receptor 2B signaling limits development of ischemic bronchiolitis obliterans organizing pneumonia. Exp Lung Res. 2017 02;43(1):38-48. PMCID: PMC5831175
69. Fisher JB, Horst A, Wan T, Kim MS, Auchampach J, Lough J. Depletion of Tip60 from In Vivo Cardiomyocytes Increases Myocyte Density, Followed by Cardiac Dysfunction, Myocyte Fallout and Lethality. PLoS One. 2016;11(10):e0164855. PMCID: PMC5074524
70. Du L, Gao ZG, Paoletta S, Wan TC, Gizewski ET, Barbour S, van Veldhoven JPD, IJzerman AP, Jacobson KA, Auchampach JA. Species differences and mechanism of action of A<sub>3</sub> adenosine receptor allosteric modulators. Purinergic Signal. 2018 03;14(1):59-71. PMCID: PMC5842153
71. Duroux R, Ciancetta A, Mannes P, Yu J, Boyapati S, Gizewski E, Yous S, Ciruela F, Auchampach JA, Gao ZG, Jacobson KA. Bitopic fluorescent antagonists of the A<sub>2A</sub> adenosine receptor based on pyrazolo[4,3-<i>e</i>][1,2,4]triazolo[1,5-<i>c</i>]pyrimidin-5-amine functionalized congeners. Medchemcomm. 2017 Aug 01;8(8):1659-1667. PMCID: PMC5729930
72. Carlin JL, Jain S, Duroux R, Suresh RR, Xiao C, Auchampach JA, Jacobson KA, Gavrilova O, Reitman ML. Activation of adenosine A<sub>2A</sub> or A<sub>2B</sub> receptors causes hypothermia in mice. Neuropharmacology. 2018 09 01;139:268-278. PMCID: PMC6067974
73. Wodsedalek DJ, Paddock SJ, Wan TC, Auchampach JA, Kenarsary A, Tsaih SW, Flister MJ, O'Meara CC. IL-13 promotes in vivo neonatal cardiomyocyte cell cycle activity and heart regeneration. Am J Physiol Heart Circ Physiol. 2019 01 01;316(1):H24-H34.
74. Tosh DK, Ciancetta A, Mannes P, Warnick E, Janowsky A, Eshleman AJ, Gizewski E, Brust TF, Bohn LM, Auchampach JA, Gao ZG, Jacobson KA. Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists. ACS Omega. 2018 Oct 31;3(10):12658-12678. PMCID: PMC6210068
75. Yu J, Mannes P, Jung YH, Ciancetta A, Bitant A, Lieberman DI, Khaznadar S, Auchampach JA, Gao ZG, Jacobson KA. Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A<sub>3</sub> adenosine receptor antagonists. Medchemcomm. 2018 Nov 01;9(11):1920-1932. PMCID: PMC6256369
76. Tosh DK, Rao H, Bitant A, Salmaso V, Mannes P, Lieberman DI, Vaughan KL, Mattison JA, Rothwell AC, Auchampach JA, Ciancetta A, Liu N, Cui Z, Gao ZG, Reitman ML, Gavrilova O, Jacobson KA. Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series. J Med Chem. 2019 02 14;62(3):1502-1522. PMCID: PMC6467784
77. Wan TC, Tampo A, Kwok WM, Auchampach JA. Ability of CP-532,903 to protect mouse hearts from ischemia/reperfusion injury is dependent on expression of A<sub>3</sub> adenosine receptors in cardiomyoyctes. Biochem Pharmacol. 2019 05;163:21-31. PMCID: PMC6470012
78. Tosh DK, Salmaso V, Rao H, Bitant A, Fisher CL, Lieberman DI, Vorbrüggen H, Reitman ML, Gavrilova O, Gao ZG, Auchampach JA, Jacobson KA. Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A<sub>3</sub> Adenosine Receptors: Affinity Enhancement by <i>N</i><sup>6</sup>-(2-Phenylethyl) Substitution. J Med Chem. 2020 04 23;63(8):4334-4348. PMCID: PMC7443318
79. Flinn MA, Otten C, Brandt ZJ, Bostrom JR, Kenarsary A, Wan TC, Auchampach JA, Abdelilah-Seyfried S, O'Meara CC, Link BA. Llgl1 regulates zebrafish cardiac development by mediating Yap stability in cardiomyocytes. Development. 2020 Aug 25;147(16). PMCID: PMC7473637
80. Wang X, Lupton C, Lauth A, Wan TC, Foster P, Patterson M, Auchampach JA, Lough JW. Evidence that the acetyltransferase Tip60 induces the DNA damage response and cell-cycle arrest in neonatal cardiomyoyctes. Journal of Molecular and Cellular Cardiology (in revision).
81. Wang X, Wan TC, Lauth A, Patterson M, Lough JW, Auchampach JA. Conditional depletion of the acetyltransferase Tip60 protects against the damaging effects of myocardial infarction. American Journal of Physiology; Heart and Circulatory Physiology (under review).
82. Tosh DK, Salmaso V, Rao H, Campbell R, Bitant A, Gao ZG, Auchampach JA, Jacobson KA. Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A<sub>3</sub> Receptor Agonists. ACS Med Chem Lett. 2020 Oct 08;11(10):1935-1941. PMCID: PMC7549272
83. Wang X, Lauth A, Wan TC, Lough JW, Auchampach JA. <i>Myh6</i>-driven Cre recombinase activates the DNA damage response and the cell cycle in the myocardium in the absence of loxP sites. Dis Model Mech. 2020 Dec 18;13(12). PMCID: PMC7758623
 
Books, Chapters, and Reviews
1. Auchampach JA, Maruyama M, Gross GJ (1994). Cardioprotective actions of potassium channel openers. European Heart Journal 15(Suppl C):89-94.
2. Gross GJ, Auchampach JA, Maruyama M, Warltier DC, Pieper GM (1992). Cardioprotective effects of nicorandil. Journal of Cardiovascular Pharmacology 20:522-528.
3. Gross GJ, Auchampach JA (1992). Role of ATP-dependent potassium channels in myocardial ischemia. Cardiovascular Research 26:1011-1016.
4. Gross GJ, Yao Z, Pieper GM, Auchampach JA (1993). The ATP-regulated potassium channel in ischemia-reperfusion injury. Annals of the New York Academy of Sciences 723:71-81.
5. Auchampach JA, Gross GJ (1993). Anti-ischemic actions of potassium channel openers in experimental myocardial ischemia/reperfusion injury. European Heart Journal 14(Suppl B):10-15.
6. Gross GJ, Yao Z, Auchampach JA (1994). Role of ATP-sensitive potassium channels in ischemic preconditioning. In: Ischemic preconditioning: The concept of endogenous cardioprotection. Ed. Przyklenk K, Kloner R, and Yellon D. Kluwer Academic Publishers, New York, NY. pp. 125-135.
7. Gross GJ, Yao Z, Auchampach JA (1996). KATP Channels, adenosine receptors, and ischemic preconditioning. In: Purines and Myocardial Protection. Ed. Adb-Elfattah AA, Kluwer Academic Publishers, New York, NY, pp. 459-468.
8. Luthin D, Auchampach JA, Linden J (1996). Adenosine receptors. In: Biomembranes Vol. 2-Rhodopsins and G-protein linked receptors. Ed. Lee AG. JAI Press Inc, Greenwich, CN. pp. 321-347.
9. Linden J, Auchampach JA, Jin X, Figler RA (1998). The structure and function of A1 and A2B adenosine receptors. Life Sciences 62:1519-1524.
10. Auchampach JA, Tang X-L, Qiu Y, Ping P, Bolli R (1998). Late preconditioning against myocardial stunning: Pathogenesis and pathophysiology. In: Advances in Organ Biology, Vol. 6. Ed. Das D. JA1 Press, Greenwich, CN. pp 121-134.
11. Auchampach JA, Bolli R (1999). Adenosine receptor subtypes in the heart: Therapeutic opportunities and challenges. American Journal of Physiology 276:H1113-H1116.
12. Pelleg A, Vassort G, Auchampach JA. (2000). ATP and adenosine signal transductions in the cardiovascular system. In: Heart Physiology and Pathophysiology, Fourth Edition. Ed. Sperelakis N, Kurachi Y, Terzic A, Cohen M. Academic Press, San Diego, CA., pp. 633-656.
13. Fryer RM, Auchampach JA, Gross GJ (2002). Therapeutic Receptor Targets of Ischemic Preconditioning. Cardiovascular Research 55:520-525.
14. Auchampach JA, Gross GJ (2007). Reperfusion injury: Does it exist? Journal of Molecular and Cellular Cardiology. 42: 12-18.
15. Auchampach JA (2007). Adenosine receptors and angiogenesis. Circulation Research. 101: 1075-1077.
16. Headrick JP, Peart JN, Kwok WM, Auchampach JA (2010). Cardiovascular Biology of the A3 Adenosine Receptor. In: A3 Adenosine Receptors in Research and Therapy, from Experimental Pharmacology to Clinical Utility, Vol. 1. Ed. Borea PA. Springer SBM (Netherlands), pp. 189-208.
17. Gao ZG, Auchampach JA, Jacobson KA. Species dependece of A3 adenosine receptor function. Purinergic Signaling (under review).
 
Editorials, Letters to Editor, Other
1. Auchampach JA, Maas JE, Wan TC, Figler RA, Gross GG (2011). Are we putting too much stock in mice? Journal of Molecular and Cellular Cardiology 50: 584-585.
 

jenkins-FCD Prod-486 e3098984f26de787f5ecab75090d0a28e7f4f7c0